Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)
Fisher, D. J. Vale, C. L. Rydzewska, L. H. Godolphin, P. Agarwal, N. Attard, G. Chi, K. N. Clarke, N. W. Davis, I. D. Fizazi, K.
Fisher, D. J.
Vale, C. L.
Rydzewska, L. H.
Godolphin, P.
Agarwal, N.
Attard, G.
Chi, K. N.
Clarke, N. W.
Davis, I. D.
Fizazi, K.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Fisher DJ, Vale CL, Rydzewska LH, Godolphin P, Agarwal N, Attard G, et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). JOURNAL OF CLINICAL ONCOLOGY. 2025 FEB 10;43(5_SUPPL). PubMed PMID: WOS:001454740300029. English.